tiprankstipranks
Trending News
More News >

Shanghai Haohai Biological Reports Modest Revenue Growth Amid Flat Profits

Story Highlights
Shanghai Haohai Biological Reports Modest Revenue Growth Amid Flat Profits

Don’t Miss TipRanks’ Half-Year Sale

Shanghai Haohai Biological Technology Co., Ltd. Class H ( (HK:6826) ) just unveiled an update.

Shanghai Haohai Biological Technology Co., Ltd. reported a slight increase in revenue for the year ended December 31, 2024, reaching RMB2,679.67 million, a 1.7% rise from the previous year. The company’s R&D expenses also increased by 8.56%, maintaining a high percentage of revenue. Despite these increases, net profit remained flat compared to 2023. The board proposed a reduced final dividend of RMB0.60 per share, down from RMB1.00 in 2023, reflecting a cautious approach to shareholder returns.

More about Shanghai Haohai Biological Technology Co., Ltd. Class H

Shanghai Haohai Biological Technology Co., Ltd. is a joint stock company incorporated in China, focusing on the biotechnology industry. It specializes in developing and providing biological products and services, with a strong emphasis on research and development.

YTD Price Performance: 8.44%

Average Trading Volume: 465,565

Technical Sentiment Consensus Rating: Sell

Current Market Cap: HK$13.97B

Find detailed analytics on 6826 stock on TipRanks’ Stock Analysis page.

Disclaimer & DisclosureReport an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App
1